



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07F 9/6506	A1	(11) International Publication Number: WO 97/41132 (43) International Publication Date: 6 November 1997 (06.11.97)
(21) International Application Number: PCT/US97/05307 (22) International Filing Date: 1 April 1997 (01.04.97) (30) Priority Data: 60/016,515 30 April 1996 (30.04.96) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [-/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DAVIS, Edward, Mark [US/US]; 7140 104th Avenue, Zeeland, MI 49464 (US). ELLIS, James, E. [US/US]; 14187 Pheasant Run, Holland, MI 49424 (US). KATONAK, David, A. [US/US]; 5427 Bunker Hill Court, Kentwood, MI 49508 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: IMPROVED PROCESS FOR THE SYNTHESIS OF DIESTERS OF PHOSPHORIC ACID 2,5-DIOXO-4,4-DIPHENYL-IMIDAZOLIDIN-1-YLMETHYL ESTER		
(57) Abstract An improved process for the preparation of a diester of phosphoric acid 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester is described where an alkali metal phosphate is treated with a 3-(chloromethyl)- or 3-(bromomethyl)-5,5-diphenyl-2,4-imidazolidinedione to afford the desired product, as well as valuable intermediates used in the process.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

-1-

IMPROVED PROCESS FOR THE SYNTHESIS OF
DIESTERS OF PHOSPHORIC ACID
2,5-DIOXO-4,4-DIPHENYL-IMIDAZOLIDIN-1-YLMETHYL ESTER

5

BACKGROUND OF THE INVENTION

The present invention relates to an improved process for the production of diesters of phosphoric acid 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester, which are key intermediates in the preparation of 5,5-diphenyl-[(3-phosphonooxy)methyl]-2,4-imidazolidinedione disodium salt (Cerebyx®, also known as fosphenytoin sodium) described in United States Patents 4,260,769 and 4,925,860, which are herein incorporated by reference. Cerebyx® is useful as an anticonvulsant, antiepileptic, and antiarrhythmic agent.

A synthetic procedure for preparing 3-(hydroxymethyl)-5,5-diphenylhydantoin dibenzyl phosphate ester is disclosed in Varia S.A., et al., Journal of Pharmaceutical Sciences, 1984;73:1068-1073. The aforementioned procedure requires the use of silver dibenzyl phosphate. This reagent is expensive, light sensitive, and silver byproducts are difficult to remove. Thus, special procedures are required to purify the desired product.

Metal salts of dialkyl phosphates have been used for phosphorylation of alkyl halides, and in general, the cation of choice is silver (Sasse K., "Methoden der Organisation Chemis" (Houben-Weyl), Band XLI/2, Thieme Verlag, Stuttgart, 1964:302-306). Precipitation of silver halide from the reaction mixture drives the reaction to completion. Salts of dialkyl phosphates with sodium or potassium as the gegenion have been used with some substrates, but are generally considered to

-2-

be very poor nucleophiles for reaction with alkyl halides (Khorana H.G., "Some Recent Developments in the Chemistry of Phosphates of Biological Interest," John Wiley & Sons, New York, New York, 1961:13-14; 5 Zwierak A, and Kluba M., Tetrahedron, 1971;27:3163-3170; United States Patents 2,494,126, 2,494,283, and 2,494,284). In point of fact, Zwierzak A. and Kluba M., Tetrahedron, 1971;27:3163-3170 disclose that sodium or potassium salts of dialkyl phosphates are too 10 unreactive to give satisfactory phosphorylation.

We have surprisingly and unexpectedly found that alkali metal phosphate esters react with either 3-(chloromethyl)- or 3-(bromomethyl)-5,5-diphenyl-2,4-imidazolidinedione to afford diesters of phosphoric 15 acid 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester. The object of the present invention is an improved, short, efficient, and economical process that can be carried out on a manufacturing scale for the preparation of diesters of phosphoric acid 2,5-dioxo- 20 4,4-diphenyl-imidazolidin-1-ylmethyl ester. Thus, the present process avoids the use of costly and unstable reagents such as silver phosphate esters and associated silver by-products, which are difficult to remove and is amenable to large-scale synthesis.


25

SUMMARY OF THE INVENTION

Accordingly, a first aspect of the present 30 invention is an improved process for the preparation of a compound of Formula I

-3-

5




I

wherein R is aryl,
arylalkyl, or
alkyl;

10 which comprises treating a compound of Formula II


15



II

wherein X is chloro or bromo with a compound of
Formula III

20




III

25

wherein M is an alkali metal, and R is as defined above
in a solvent to afford a compound of Formula I.

A second aspect of the present invention is a
novel intermediate of Formula I

30



I

35

wherein R is aryl,
arylalkyl, or

-4-

alkyl with the exclusion of:

phosphoric acid dibenzyl ester 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester.

5

DETAILED DESCRIPTION OF THE INVENTION

10 In the compounds of Formula I, the term "alkyl" means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like.

15 The term "aryl" means an aromatic radical which is a phenyl group, a naphthyl group, unsubstituted or substituted by 1 to 4 substituents selected from alkyl as defined above, nitro or halogen.

The term "arylalkyl" means an aromatic radical attached to an alkyl radical wherein aryl and alkyl are as defined above, for example, benzyl and the like.

20 "Halogen" is fluorine, chlorine, bromine, or iodine.


"Alkali metal" is a metal in Group IA of the periodic table and includes, for example, lithium, sodium, potassium, cesium, and the like.

25 The process of the present invention is a new, improved, economical, and commercially feasible method for preparing compounds of Formula I, which are useful as intermediates in the preparation of fosphenytoin sodium, which is useful as an anticonvulsant, antiepileptic, and antiarrhythmic agent.

30 The process of the present invention is outlined in the following scheme:

-5-

Scheme I



-6-

A compound of Formula I wherein R is aryl, arylalkyl, or alkyl is prepared by reacting a compound of Formula II wherein X is chlorine or bromine with a compound of Formula III wherein M is an alkali metal such as, for example, lithium, sodium, potassium, cesium, and the like, and R is as defined above in a solvent such as, for example, acetonitrile and the like at about 25°C to about the reflux temperature of the solvent for about 1 hour to about 24 hours to afford a compound of Formula I. When M is potassium, optionally a catalytic amount of potassium iodide may be used. When M is sodium, optionally a catalytic amount of tetrabutylammonium iodide or 18-crown-6 may be used. Preferably, the reaction is carried out in acetonitrile at reflux for about 2 hours to about 11 hours.

5,5-Diphenyl-2,4-imidazolidinedione (phenytoin) is readily available or may be prepared according to procedures disclosed in United States Patent Number 2,409,154.

Compounds of Formula III are either known or capable of being prepared by methods known in the art.

The following examples are illustrative to show the present process, the preparation of starting materials, and the use of a compound of Formula I obtained by the present process to prepare 5,5-diphenyl-[(3-phosphonooxy)methyl]-2,4-imidazolidinedione disodium salt useful as an anticonvulsant, antiepileptic, and antiarrhythmic agent.

EXAMPLE 1

Phosphoric acid dibenzyl ester 2,5-Dioxo-4,4-diphenyl-1-imidazolidin-1-ylmethyl ester

Step (A): Preparation of 3-(Chloromethyl)-5,5-diphenyl-2,4-imidazolidinedione

-7-

A mixture of 250 kg 5,5-diphenyl-2,4-imidazolidinedione (phenytoin), 2.6 kg of potassium carbonate, and 454 L ethyl alcohol is heated to 70°C to 80°C. One hundred twenty-five kilograms of 37% formaldehyde solution is added, and heating is continued for at least 2 hours. The reaction mixture is cooled slowly, and 600 L of water is added during the cooling cycle. The resulting slurry is cooled to less than 25°C. The product, 3-hydroxymethyl-5,5-diphenyl-2,4-imidazolidinedione, is collected by filtration and washed with water. The wet cake is dried at 20°C to 50°C. The dried product and 1350 kg of ethyl acetate are charged to a reactor. Five kilograms of dimethyl formamide and 135 kg of thionyl chloride are added at 25°C to 35°C. The reaction mixture is heated to 35°C to 60°C for about 2 hours or until the reaction is essentially complete. The reaction mixture is cooled to 20°C to 30°C and combined with 2200 L of aqueous sodium bicarbonate. The organic layer is separated and concentrated by distillation. Heptane is added, and the resulting slurry is cooled. The title compound is collected by filtration and washed with heptane. The wet cake is dried at 20°C to 50°C under vacuum to give 3-(chloromethyl)-5,5-diphenyl-2,4-imidazolidinedione, 268 kg (90% yield); mp 161.2-161.8°C.

Step (B): Preparation of Phosphoric acid dibenzyl ester
2,5-dioxo-4,4-diphenyl-imidazolidin-1-
ylmethyl ester

Method A

A mixture of 250 kg 3-(chloromethyl)-5,5-diphenyl-2,4-imidazolidinedione from Step (A), 270 kg of potassium dibenzyl phosphate, 6 kg of potassium carbonate, 0.75 kg of potassium iodide, and 500 kg of acetonitrile is heated at 70°C to reflux for 2 to

-8-

5 hours or until the reaction is essentially complete. The reaction mixture is cooled to 40°C to 65°C and filtered. The solution is stirred with at least 11 kg of activated carbon and filtered using a filter-aid.

5 The reaction solvent is replaced by adding toluene in portions and vacuum distilling. The resulting slurry is cooled to less than 5°C. The title compound is collected by filtration and washed with cold toluene. The wet cake is dried at 50°C under vacuum to give

10 phosphoric acid dibenzyl ester 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester, 315 kg (70% yield); mp 118.6-119.7°C.

Method B

15 Ten grams of 3-(chloromethyl)-5,5-diphenyl-2,4-imidazolidinedione from Step (A), 10.3 g of sodium dibenzyl phosphate, and 0.5 g of sodium carbonate were slurried into 50 mL acetonitrile. The reaction mixture was heated at reflux for 11 hours. The solution was

20 filtered to remove sodium chloride precipitate. The filtrate volume was reduced under vacuum, then 40 mL of toluene added. The solution was seeded and cooled to 0°C. The product was filtered and dried under vacuum at 40°C. 7.38 Grams of the title compound was obtained

25 (43% yield) (product identical with Method A product by high pressure liquid chromatography (HPLC) retention time).

Method C

30 Ten grams of 3-(chloromethyl)-5,5-diphenyl-2,4-imidazolidinedione from Step (A), 14 g of cesium dibenzyl phosphate, and 0.48 g of cesium carbonate were slurried into 50 mL acetonitrile. The reaction mixture was heated at reflux for 4 hours. The solution was

35 filtered to remove cesium chloride precipitate. The filtrate volume was reduced under vacuum. The solution

-9-

was seeded and cooled to 0°C. The product was filtered and dried under vacuum at 40°C. 11.5 Grams of the title compound was obtained (63.9% yield) (product identical with Method A product by HPLC retention time).

EXAMPLE 2

Phosphoric acid 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester dimethyl ester

Thirty grams of 3-(chloromethyl)-5,5-diphenyl-2,4-imidazolidinedione from Step (A), 17.1 g of potassium dimethyl phosphate, 0.6 g of potassium carbonate, and 0.15 g of potassium iodide were slurried into 75 mL of acetonitrile. The reaction mixture was heated at reflux for 3 hours. The solution was filtered to remove potassium chloride precipitate and concentrated to thick oil. Isopropyl alcohol was added to the oil and cooled to 0°C. The product was filtered and dried under vacuum. Sixteen grams of the title compound was obtained (40.9% yield); mp 123.1-124.3°C. Proton nuclear magnetic resonance spectroscopy (¹H NMR) deuterated dimethyl sulfoxide (DMSO-d₆): 3.6 ppm (d, 6H), 5.3 (d, 2H), 7.3-7.5 (m, 10H), 10.0 (s, 1H); doublets from long range phosphorous coupling.

EXAMPLE 3

Phosphoric acid dibutyl ester 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester

23.1 Grams of di(n-butyl)phosphate and 6.2 g of potassium hydroxide were slurried into 100 mL of t-butyl methyl ether. The reaction was stirred until homogeneous and concentrated under vacuum to thick oil of potassium di(n-butyl)phosphate. The oil, along with 30 g of 3-(chloromethyl)-5,5-diphenyl-2,4-imidazolidinedione from Step (A), 0.6 g of potassium carbonate, and 0.15 g of potassium iodide was slurried

-10-

into 75 mL of acetonitrile. The reaction mixture was heated at reflux for 2.5 hours. The solution was filtered to remove potassium chloride precipitate and then concentrated under vacuum. The residue was
5 crystallized from ethyl acetate/heptane to give 32.8 g of the title compound (69.2% yield); mp 94.8-96.9°C. ¹H NMR (DMSO-d₆): 0.8 ppm (t, 3H), 1.2 (dq, 2H), 1.45 (dt, 2H), 3.85 (dq, 2H), 5.3 (d, 2H), 7.3-7.5 (m, 10H), 9.8 (s, 1H) (peaks at 3.85 and 5.3 doublets from long
10 range phosphorus coupling).

EXAMPLE 4

Phosphoric acid di-tert-butyl ester 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester

15 35.5 Grams of 3-(chloromethyl)-5,5-diphenyl-2,4-imidazolidinedione from Step (A), 30.7 g of potassium di(t-butyl) phosphate, 0.6 g of potassium carbonate, and 0.15 g of potassium iodide were slurried into 200 mL acetonitrile. The reaction mixture was heated
20 at reflux for 2.5 hours. The solution was filtered to remove potassium chloride precipitate. The filtrate was cooled to 0°C and filtered to give 22.3 g of the title compound (38.6% yield); mp 108.5°C (d). ¹H NMR (DMSO-d₆): 1.3 ppm (s, 18H), 5.2 (d, 2H),
25 7.3-7.5 (m, 10H), 9.9 (s, 1H); doublet from long range phosphorus coupling.

EXAMPLE 5

5,5-Diphenyl-[(3-phosphonooxy)methyl]-2,4-imidazolidinedione disodium salt

30 A mixture of 250 kg phosphoric acid dibenzyl ester 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester (Example 1, Step (B)), 9 kg of activated carbon (optionally filter-aid may be added), and 1025 L of
35 acetone is heated at a temperature range of 45°C to reflux. The activated carbon is removed by filtration.


-11-

The filtrate is charged to a hydrogenator containing about 6.6 kg of palladium on carbon (50% water wet), and the total water is adjusted to about 28 L. The hydrogenation is run at 20°C to 40°C and continued until hydrogen uptake diminishes. The mixture is filtered to remove the catalyst. A minimum of 700 L of water is added, and the solution is concentrated by vacuum distillation at a pot temperature of less than 60°C. The pH of the solution is adjusted to 8.2 to 8.9 with dilute aqueous sodium hydroxide and dilute hydrochloric acid while maintaining a solution temperature of 20°C to 35°C. At least 27.5 kg of activated carbon is added to the solution. The solution is filtered using a filter-aid. Acetone is added, and the resulting slurry is cooled. The product is collected by filtration, washed with acetone, and dried at 20°C to 25°C under vacuum to give the title compound 168 kg (90% yield) on an anhydrous basis. ¹H NMR deuterated water (D₂O): 5.2 ppm (d, 2H), 7.35-7.5 (m, 10H); NH proton exchanged in D₂O, doublet from long range phosphorus coupling.

-12-


CLAIMS

1. A process for the preparation of a compound of Formula I



10
 wherein R is aryl,
 arylalkyl, or
 alkyl;

which comprises treating a compound of Formula II



20
 wherein X is chloro or bromo with a compound of
 Formula III



30
 wherein M is an alkali metal, and R is as defined
 above in a solvent to afford a compound of
 Formula I.

2. A process according to Claim 1 wherein the solvent
 is acetonitrile.

-13-

3. A process according to Claim 1 for the preparation of a compound selected from the group consisting of:

Phosphoric acid dibenzyl ester 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester;

Phosphoric acid 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester dimethyl ester;

Phosphoric acid dibutyl ester 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester; and

Phosphoric acid di-tert-butyl ester 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester.

4. A process according to Claim 3 for the preparation of phosphoric acid dibenzyl ester 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester.


5. A process according to Claim 1 wherein the compound of Formula II is 3-(chloromethyl)-5,5-diphenyl-2,4-imidazolidinedione.

6. A process according to Claim 1 wherein a compound of Formula III is selected from the group consisting of: potassium dibenzyl phosphate; sodium dibenzyl phosphate; cesium dibenzyl phosphate; potassium dimethyl phosphate; sodium dimethyl phosphate; cesium dimethyl phosphate; potassium di(n-butyl) phosphate; sodium di(n-butyl) phosphate; potassium di(t-butyl) phosphate; sodium di(t-butyl) phosphate; and cesium di(t-butyl) phosphate.

7. A process according to Claim 6 wherein the compound of Formula III is potassium dibenzyl phosphate.

-14-

8. A compound of Formula I



10 wherein R is aryl,
aryalkyl, or
alkyl with the exclusion of:
phosphoric acid dibenzyl ester
2,5-dioxo-4,4-diphenyl-imidazolidin-1-
ylmethyl ester.

9. A compound according to Claim 8 which is selected from the group consisting of:

5 Phosphoric acid 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester dimethyl ester;
Phosphoric acid dibutyl ester 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester; and
Phosphoric acid di-tert-butyl ester
2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester.

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07F9/6506

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. PHARM. SCI. (JPMSAE,00223549);84; VOL.73 (8); PP.1068-73, UNIV. KANSAS;SCH. PHARM.; LAWRENCE; 66045; KS; USA (US), XP000604620 VARIA S A ET AL: "Phenytoin prodrugs. III: Water-soluble prodrugs for oral and/or parenteral use" cited in the application see the whole document ---	1-9
A	TETRAHEDRON, (INCL TETRAHEDRON REPORTS), vol. 27, no. 14, 1971, OXFORD GB, pages 3163-3170, XP002033824 A. ZWIERZAK: "Organophosphorus esters-I" cited in the application see the whole document --- -/--	1-9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

26 June 1997

Date of mailing of the international search report

08.07.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Beslier, L

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 260 769 A (VALENTINO G. STELLA) 7 April 1981 cited in the application see the whole document ---	1-9
A	EP 0 069 881 A (BAYER AG) 19 January 1983 see claim 6; example 1.A ---	1-9
A	US 2 494 126 A (ERICK I. HOEGBERG) 10 January 1950 cited in the application see claim 5; example 9 -----	1-9

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4260769 A	07-04-81	US 4163058 A	31-07-79
EP 69881 A	19-01-83	DE 3126390 A	13-01-83
		AU 8546582 A	06-01-83
		BR 8203894 A	28-06-83
		JP 58010597 A	21-01-83
US 2494126 A	10-01-50	BE 489216 A	
		CH 289005 A	
		DE 807687 C	
		FR 986120 A	27-07-51
		GB 664779 A	